INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc.

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

IPO Year: 2021

Exchange: NASDAQ

Website: minktherapeutics.com

Peers

$AGEN

Recent Analyst Ratings for MiNK Therapeutics Inc.

Date	Price Target	Rating	Analyst
1/24/2022	$24.00 → $10.00	Buy	B. Riley Securities
11/9/2021	$24.00	Buy	B. Riley Securities
11/9/2021	$26.00	Outperform	Robert W. Baird
11/9/2021		Outperform	William Blair
11/9/2021	$30.00	Outperform	Evercore ISI Group
11/9/2021	$26.00	Outperform	Baird

See more ratings

MiNK Therapeutics Inc.

Peers

Recent Analyst Ratings for MiNK Therapeutics Inc.

MiNK Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Corvese Brian was granted 2,494 shares, increasing direct ownership by 6% to 47,151 units (SEC Form 4)

Director Behner Peter was granted 2,267 shares, increasing direct ownership by 15% to 17,476 units (SEC Form 4)

Director Kadlec Robert Peter was granted 1,883 shares, increasing direct ownership by 68% to 4,647 units (SEC Form 4)

Director Wiinberg Ulf was granted 1,953 shares, increasing direct ownership by 12% to 17,960 units (SEC Form 4)

Director Ryan Barbara was granted 2,476 shares, increasing direct ownership by 15% to 19,524 units (SEC Form 4)

Director Kadlec Robert Peter was granted 1,536 shares, increasing direct ownership by 125% to 2,764 units (SEC Form 4)

Director Behner Peter was granted 1,849 shares, increasing direct ownership by 14% to 15,209 units (SEC Form 4)

Director Wiinberg Ulf was granted 1,593 shares, increasing direct ownership by 11% to 16,007 units (SEC Form 4)

Director Corvese Brian was granted 2,033 shares, increasing direct ownership by 5% to 44,657 units (SEC Form 4)

Director Ryan Barbara was granted 2,019 shares, increasing direct ownership by 13% to 17,048 units (SEC Form 4)

MiNK Therapeutics Inc. SEC Filings

MiNK Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by MiNK Therapeutics Inc.

MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by MiNK Therapeutics Inc.

SEC Form PRE 14A filed by MiNK Therapeutics Inc.

SEC Form 10-K filed by MiNK Therapeutics Inc.

MiNK Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by MiNK Therapeutics Inc.

SEC Form DEF 14A filed by MiNK Therapeutics Inc.

SEC Form PRE 14A filed by MiNK Therapeutics Inc.

MiNK Therapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Agenus Inc bought $25,270 worth of shares (22,975 units at $1.10), increasing direct ownership by 0.11% to 21,772,863 units (SEC Form 4)

Agenus Inc bought $16,380 worth of shares (15,001 units at $1.09), increasing direct ownership by 0.07% to 21,749,888 units (SEC Form 4)